Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Feb 7, 2013; 19(5): 721-726
Published online Feb 7, 2013. doi: 10.3748/wjg.v19.i5.721
Published online Feb 7, 2013. doi: 10.3748/wjg.v19.i5.721
Table 1 Baseline demographics (n = 163) n (%)
| Age (yr) | |
| Mean age | 52.0 (24-86) |
| Mean age at start | 47.4 (20-81) |
| Gender | |
| Males | 113 (69.3) |
| Females | 50 (30.7) |
| Pre-treatment Biopsies | 134 (82.2) |
| Duration of therapy (mo) | |
| Range | 3-46 |
| Mean | 25.63 |
| Median | 23 |
| Patients > 24 mo | 79 (48.5) |
| Patients > 36 mo | 49 (30.1) |
| Co-infection | |
| Hepatitis C | 1 (0.61) |
| HBV DNA load (IU/mL) | |
| > 100 000 | 95 (58.3) |
| 2000-100 000 | 45 (27.6) |
| 12-2000 | 23 (14.1) |
| HBe antigen status | 41 (25.2) |
| e antigen positive | 112 (68.7) |
| e antigen negative | 10 (6.1) |
| Unknown | |
| ALT (U/L) | |
| 10-40 | 39 (23.9) |
| 40-400 | 118 (72.4) |
| > 400 | 5 (3.01) |
| Unknown | 1 (0.61) |
| Fibrosis score | 0-10 (6.13) |
| 135 (82.82%) | 1-61 (37. 4) |
| 2-38 (23.3) | |
| 3-17 (10.4) | |
| 4-9 (5.52) | |
| Unknown-27 (16.6) |
Table 2 Follow up of DNA values and cumulative rates of complete and partial virological suppression n (%)
| Month | 0 | 6 | 12 | 18 | 24 | 30 | 36 | 42 |
| Patients with DNA | 163 (100) | 158 (96.9) | 141 (86.5) | 121 (74.2) | 105 (64.4) | 76 (46.6) | 56 (34.4) | 24 (14.7) |
| Complete virological suppression | 0/169 (0) | 104/158 (65.8) | 117/141 (83.0 ) | 96/121 (74.4) | 94/105 (89.5) | 65/76 (85.5) | 46/56 (82.1) | 19/24 (79.2) |
| Cumulative CVS | 0% | 66.7% | 88.8% | 85.1% | 94.8% | 93.2% | 92.2% | 91.6% |
| Partial virological suppression | 22/163 (13.5) | 141/158 (89.2) | 133/141 (94.3) | 117/121 (90.7) | 100/105 (95.2) | 75/76 (98.7) | 54/56 (96.4) | 23/24 (95.8) |
| Cumulative PVS | 13.5% | 89.2% | 94.9% | 92.1% | 96.3% | 99.0% | 97.3% | 96.6% |
Table 3 Complete virological suppression based on age and HBeAg status
| Age-log rank 0.001 (median) | ||
| < 40 yr- | 40-55 yr- | > 55 yr- |
| 12 mo (9.25-14.75) | 6 mo (5.01-6.99) | 6 mo (5.24-6.76) |
| Hepatitis B e antigen negative status-log rank 0.19 (median) | ||
| < 40 yr- | 40-55 yr- | > 55 yr- |
| 6 mo (4.05-7.95) | 6 mo (4.99-7.02) | 6 mo (5.59-6.41) |
| Hepatitis B e antigen positive status-log rank 0.19 (median) | ||
| < 40 yr- | 40-55 yr- | > 55 yr- |
| 18 mo (7.37-28.63) | 18 mo (14.17-26.47) | 6 mo (6.5-17.5) |
| Hepatitis B e antigen seroconversion rate based on age-log rank 0.559 (median) | ||
| < 40 yr- | 40-55 yr- | > 55 yr- |
| 36 mo (20.55-51.45) | 30 mo (18.46-41.54) | 6 mo (9.8-32.2) |
- Citation: Fahrtash-Bahin F, Kariyawasam VC, Gray T, Byth K, George J, Douglas MW. Australian tertiary care outcomes of entecavir monotherapy in treatment naive patients with chronic hepatitis B. World J Gastroenterol 2013; 19(5): 721-726
- URL: https://www.wjgnet.com/1007-9327/full/v19/i5/721.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i5.721